Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.52 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.52 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TXN | P10599 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24393527 | 0.90 | EHMT2 (0.48) | EHMT2EHMT1APOBEC3GHPGDMEN1 | |
| SCHEMBL17486505 | 0.86 | EHMT2 (0.44) | EHMT2EHMT1APOBEC3GHPGDMEN1 | |
| SCHEMBL20131103 | 0.86 | EHMT2 (0.55) | EHMT2EHMT1APOBEC3GHPGDMEN1 | |
| SCHEMBL4909274 | 0.86 | EHMT2 (0.55) | EHMT2EHMT1APOBEC3GHPGDMEN1 | |
| SCHEMBL12337156 | 0.85 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHPGDMEN1 | |
| SCHEMBL20261217 | 0.83 | EHMT2 (0.45) | EHMT2EHMT1APOBEC3GHPGDMEN1 | |
| SCHEMBL16710880 | 0.83 | EHMT2 (0.47) | EHMT2EHMT1APOBEC3GHPGDMEN1 | |
| SCHEMBL10327179 | 0.83 | EHMT2 (0.47) | EHMT2EHMT1APOBEC3GHPGDMEN1 | |
| SCHEMBL15301066 | 0.81 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHPGDMEN1 | |
| SCHEMBL15912395 | 0.81 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293869-B2 | Polymer conjugates of GLP-1 | NEKTAR THERAPEUTICS (US) | 2012-10-23 | — | — | US | disclosed |
| US-8273339-B2 | Polymer-based compositions and conjugates of antimicrobial agents | NEKTAR THERAPEUTICS (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120195847-A1 | POLYMER CONJUGATES OF BIPHALIN PEPTIDES | NEKTAR THERAPEUTICS (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110318322-A1 | Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer | NEKTAR THERAPEUTICS (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110237524-A1 | POLYMER CONJUGATES OF AOD-LIKE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110171162-A1 | POLYMER CONJUGATES OF THYMOSIN ALPHA 1 PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171164-A1 | POLYMER CONJUGATES OF GLP-2-LIKE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171163-A1 | POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20100210505-A1 | POLYMER CONJUGATES OF GLP-1 | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100160610-A1 | Conjugates of an EPO Moiety and a Polymer | NEKTAR THERAPEUTICS (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100137511-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171163-A1 | POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES | NGLY1, VIP, IAPP | EHMT2 3843/4885EHMT1 3513/4885APOBEC3G 3127/4885 |
| US-20110237524-A1 | POLYMER CONJUGATES OF AOD-LIKE PEPTIDES | NGLY1, OCIAD1, TAP1 | EHMT2 4234/4885EHMT1 3956/4885APOBEC3G 1418/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | EHMT2 4036/4885EHMT1 4096/4885APOBEC3G 836/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | EHMT2 4337/4885EHMT1 4185/4885APOBEC3G 2236/4885 |
| US-20100210505-A1 | POLYMER CONJUGATES OF GLP-1 | GLP1R, GIPR, NGLY1 | EHMT2 564/4885EHMT1 165/4885APOBEC3G 4272/4885 |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | EHMT2 3972/4885EHMT1 4001/4885APOBEC3G 852/4885 |
| US-20110171162-A1 | POLYMER CONJUGATES OF THYMOSIN ALPHA 1 PEPTIDES | TMSB4X, TMSB10, TAP1 | EHMT2 3834/4885EHMT1 2352/4885APOBEC3G 2017/4885 |
| US-20120195847-A1 | POLYMER CONJUGATES OF BIPHALIN PEPTIDES | NGLY1, DNPEP, CIAPIN1 | EHMT2 4079/4885EHMT1 3508/4885APOBEC3G 3509/4885 |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | EHMT2 3972/4885EHMT1 4001/4885APOBEC3G 852/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | EHMT2 3945/4885EHMT1 3315/4885APOBEC3G 2430/4885 |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | SLC19A1, FOLR1, SLC46A1 | EHMT2 2504/4885EHMT1 2680/4885APOBEC3G 2436/4885 |
| US-20100137511-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | EHMT2 3972/4885EHMT1 4001/4885APOBEC3G 852/4885 |
| US-20100160610-A1 | Conjugates of an EPO Moiety and a Polymer | EPOR, EPRS1, NPPA | EHMT2 3486/4885EHMT1 3216/4885APOBEC3G 3735/4885 |
| US-20110171164-A1 | POLYMER CONJUGATES OF GLP-2-LIKE PEPTIDES | IAPP, GLP1R, GIPR | EHMT2 781/4885EHMT1 2327/4885APOBEC3G 3067/4885 |
| US-20110318322-A1 | Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer | GAA, MAN2B1, GBA1 | EHMT2 3463/4885EHMT1 3228/4885APOBEC3G 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.